Markets Stocks Economy Crypto Earnings Banking Energy
Home› Stocks› Feature
Stocks · Exclusive

European Stocks Slip as Novo Nordisk Data and Nokia AI Bid Draw Focus

European Stocks Slip as Novo Nordisk Data and Nokia AI Bid Draw Focus
Stocks · 2026
Photo · Eleanor Whitfield for Daily Digest Invest
By Eleanor Whitfield Markets Editor-in-Chief Nov 16, 2026 4 min read

European equities drifted lower on Monday, a subdued start to the trading week as investors weighed a pair of high-profile corporate updates against lingering geopolitical uncertainty. The pan-European Stoxx 600 and major national benchmarks slipped modestly, with gains in healthcare and technology names failing to offset broader caution.

The two stories drawing the most attention were Novo Nordisk's latest clinical data for its experimental obesity drug CagriSema and a Nokia-led consortium bidding to build AI-focused supercomputers under the EuroHPC JU programme. Both developments landed as market participants looked ahead to a planned Thursday summit involving U.S. President Donald Trump, Russian President Vladimir Putin and Chinese President Xi Jinping.

Novo Nordisk's CagriSema update

Novo Nordisk, the Danish pharmaceutical giant behind blockbuster weight-loss and diabetes treatments Ozempic and Wegovy, released fresh trial data for CagriSema, its next-generation combination therapy. CagriSema pairs semaglutide — the active ingredient in Wegovy — with cagrilintide, a separate compound designed to enhance feelings of fullness. The drug is central to Novo's efforts to defend its lead in the rapidly growing obesity-treatment market.

For everyday investors, the key takeaway is that Novo's pipeline remains a major swing factor for European healthcare stocks. The company's shares have been volatile over the past year as rivals race to bring competing obesity drugs to market. Any data that suggests CagriSema could match or exceed existing treatments tends to support the stock; disappointing results can trigger sharp selloffs. Monday's update was enough to give drugmakers a modest lift, though the broader market remained cautious.

The obesity-drug space has become one of the most closely watched corners of global healthcare investing. Analysts estimate the market could be worth tens of billions of dollars annually within the next decade, and Novo is competing fiercely with U.S. rival Eli Lilly. Trial readouts like Monday's are therefore treated as important signposts for the entire sector, not just for Novo.

Nokia and the AI infrastructure race

Separately, Nokia joined a Nordic-Baltic consortium bidding to build AI gigafactories under the EuroHPC JU initiative — a European Union programme aimed at expanding the continent's high-performance computing capacity. The bid reflects a broader push by European governments and companies to close the gap with the U.S. and China in artificial intelligence infrastructure.

AI gigafactories are essentially large-scale data centres packed with specialised chips designed to train and run advanced AI models. They require enormous amounts of electricity, cooling and networking equipment — areas where Nokia's infrastructure business has a role to play. For investors, the news is a reminder that the AI trade extends well beyond the chipmakers that dominate headlines. Telecom equipment suppliers, data-centre operators and power utilities are all part of the ecosystem.

European policymakers have made AI sovereignty a priority, arguing the bloc needs its own computing capacity rather than relying entirely on American or Chinese providers. That policy backdrop could translate into long-term contracts for companies involved in these projects, though the financial impact is likely to unfold over years rather than quarters.

What it means for investors

Monday's session illustrates a familiar pattern in European markets: sector-specific news can move individual stocks, but broader indexes often take their cue from macroeconomic and geopolitical factors. With the Trump-Putin-Xi summit scheduled for Thursday, investors appear reluctant to make large directional bets early in the week.

Summits of this kind are watched closely because they can signal shifts in trade policy, energy supply and global security — all of which feed into corporate earnings and investor risk appetite. Any concrete agreements on tariffs, energy flows or technology restrictions could move markets in either direction. In the absence of clarity, trading volumes often thin out and volatility can pick up around the event itself.

For ordinary investors, the practical implications are twofold. First, healthcare and AI-infrastructure names remain areas where company-specific news can create meaningful share-price moves, even on days when the wider market is flat. Second, geopolitical events are a reminder that diversification across regions and sectors helps cushion portfolios against headline-driven swings.

Investors will also be watching for follow-through on both corporate stories. Novo Nordisk's CagriSema programme faces further trial milestones and eventual regulatory review, while the EuroHPC JU bid process will take time to resolve. Neither is likely to deliver an immediate earnings boost, but both feed into longer-term narratives that have been driving European equity flows.

With the summit on the horizon and a busy corporate calendar ahead, European markets look set for a week where headlines — rather than fundamentals alone — dictate the tone.

More from this story

Next article · Don't miss

TSX slides to six-week low as AI jitters hit tech shares

Canada's main stock index dropped to its lowest close in nearly six weeks, dragged down by tech and industrial shares as investors grew nervous ahead of Nvidia's earnings. Materials edged higher after Panama agreed to reopen talks on First Quantum's Cobre Pana

Read the story →
TSX slides to six-week low as AI jitters hit tech shares